Journal of Clinical Endocrinology & Metabolism, Vol 80, 3088-3090, Copyright © 1995 by Endocrine Society

ARTICLES

Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas

J Zedenius, C Larsson, U Bergholm, J Bovee, A Svensson, B Hallengren, L Grimelius, M Backdahl, G Weber and G Wallin
Department of Surgery, Karolinska Hospital, Stockholm, Sweden.

The hereditary multiple endocrine neoplasia syndromes types 2A and B (MEN 2A and B) were recently linked to germline mutations in the RET proto-oncogene, altering one of five cysteine residues in exon 10 or 11 (MEN 2A), or substituting a methionine for a threonine at codon 918 in exon 16 (MEN 2B). The latter mutation also occurs somatically in some sporadic medullary thyroid carcinomas (MTC), and has in a previous study been correlated with a less favorable clinical outcome. In the present study, 46 MTCs were selected for investigation of the codon 918 mutation. The mutation was found in 29 tumors (63%), and was significantly correlated with a poor outcome, with regard to distant metastasis or tumor recurrence (p < 10(-4)). Two tumors showed multifocal growth and C-cell hyperplasia, and these patients were therefore also investigated for germline mutations in exons 10, 11 and 16. The codon 918 mutation was found only in the tumors, thus of somatic origin. The RET codon 918 mutation may have prognostic impact, and therefore preoperative assessment may influence decision-making in the treatment of patients suffering from MTC.

This article has been cited by other articles:

				D. Hong, L. Ye, R. Gagel, L. Chintala, A. K. El Naggar, J. Wright, and R. Kurzrock Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib Mol. Cancer Ther., May 1, 2008; 7(5): 1001 - 1006. [Abstract] [Full Text] [PDF]

				R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, et al. Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 682 - 687. [Abstract] [Full Text] [PDF]

				D. J. Marsh, G. Theodosopoulos, K. Martin-Schulte, A.-L. Richardson, J. Philips, H.-D. Roher, L. Delbridge, and B. G. Robinson Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1866 - 1872. [Abstract] [Full Text] [PDF]

				M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5658 - 5671. [Abstract] [Full Text] [PDF]

				L. Quadro, O. Fattoruso, M. P. Cosma, U. Verga, A. Porcellini, A. Libroia, and V. Colantuoni Loss of Heterozygosity at the RET Protooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 239 - 244. [Abstract] [Full Text]

				S. U. Goebel, C. Heppner, A. L. Burns, S. J. Marx, A. M. Spiegel, Z. Zhuang, I. A. Lubensky, F. Gibril, R. T. Jensen, and J. Serrano Genotype/Phenotype Correlation of Multiple Endocrine Neoplasia Type 1 Gene Mutations in Sporadic Gastrinomas J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 116 - 123. [Abstract] [Full Text]

				C. Eng RET Proto-Oncogene in the Development of Human Cancer J. Clin. Oncol., January 1, 1999; 17(1): 380 - 380. [Abstract] [Full Text] [PDF]

				C. Eng, G. A. Thomas, D. S. Neuberg, L. M. Mulligan, C. S. Healey, C. Houghton, A. Frilling, F. Raue, E. D. Williams, and B. A. J. Ponder Mutation of the RET Proto-Oncogene Is Correlated with RET Immunostaining in Subpopulations of Cells in Sporadic Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4310 - 4313. [Abstract] [Full Text]

				R. R. de Krijger, A. Brooks, E. van der Harst, R. M. W. Hofstra, H. A. Bruining, J. C. Molenaar, and C. Meijers Constipation as the Presenting Symptom in De Novo Multiple Endocrine Neoplasia Type 2B Pediatrics, August 1, 1998; 102(2): 405 - 407. [Full Text] [PDF]

				D. J. Marsh, Z. Zheng, A. Arnold, S. D. Andrew, D. Learoyd, A. Frilling, P. Komminoth, H. P.H. Neumann, B. A.J. Ponder, B. J. Rollins, et al. Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3025 - 3028. [Abstract] [Full Text] [PDF]

				C. Eng The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease N. Engl. J. Med., September 26, 1996; 335(13): 943 - 951. [Full Text] [PDF]